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ACE–PrEvEntion PAmPhlEts  
GEnErAl PoPulAtion rEsults PAmPhlEt 3:
Cost-EffECtivEnEss of blood PrEssurE And CholEstErol 
lowErinG intErvEntions
1. Main Messages
It is possible to increase by 36% the amount of health gain from primary cardiovascular disease prevention at 
one third of current levels of expenditure by:-
•	 adopting absolute risk as the clinical indication for prevention therapy;
•	 greater use of the less expensive drug therapies; and
•	 greater use of the effective non-drug therapies.
The polypill (three blood pressure lowering drugs at half strength, and a statin) is starting to show effectiveness 
in trials as predicted and would become the most cost-effective preventive drug treatment at an annual cost 
per patient of $200.
2. Background
Cardiovascular disease was the second largest cause of DALYs in 2003 in Australia. The main clinical 
manifestations of cardiovascular disease are heart attacks, angina (pain on the chest), heart failure and stroke. 
Significant gains have been made in recent decades with mortality from coronary and stroke events falling by 
70% despite more obesity and less physical activity. Yet, the burden of this largely preventable chronic disease 
can still be reduced much further. Interventions that address nutrition, body mass index, smoking and physical 
activity can also contribute to reducing the burden of cardiovascular disease in Australia, but are reported 
on elsewhere in this project. It is important to note that Government expenditure on cardiovascular drugs 
represents approx 30% of the total outlay on the Pharmaceutical Benefit Scheme and that most of these drugs 
are blood pressure and cholesterol lowering drugs used in primary prevention and by those who have disease. 
This pamphlet focuses on the cost-effectiveness of blood pressure and cholesterol lowering interventions in 
the primary prevention of cardiovascular disease in the Australian general population and highlights policy 
implications.
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3. interVentions
We updated the economic evaluation analysis carried out in a previous ACE study (ACE Heart disease) which was based on extensive 
literature reviews and meta-analyses that summarised the available evidence of effectiveness of the following interventions in 2003. 
To the list of currently available interventions has been added the novel Polypill medication which is generating interesting results in 
clinical trials during 2009. Interventions are targeted at persons without previous cardiovascular disease, in three categories of absolute 
risk of a coronary or stroke event in the next 5 years (>5% risk, >10% risk, >15% risk). Absolute risk takes into account the combined risk 
of multiple risk factors, including tobacco smoking, body weight, blood pressure, cholesterol, age and sex.
cHolesterol lowering strategies
1. Community heart health program: A population-wide program of social marketing and education aimed at increasing healthy 
lifestyles and the reduction of cardiovascular disease risk factors.
2. Dietary counselling by a dietician: The provision of dietary advice by a dietician to an individual for several weeks 
3. Dietary counselling by a GP: The provision of dietary advice by a GP to an individual for several weeks 
4. Promotion of phytosterol or phytostanol supplementation: Substitution of normal butter/margarine with phytosterol-enriched 
margarine (brand names Proactive, Logicol)
5. Statin drug therapy: cholesterol-lowering medication in conjunction with monitoring and follow up with general practitioner visits 
and blood tests. 
6. Combination drug therapy with a statin plus ezitimibe: Medications given in combination in conjunction with monitoring and 
follow up with general practitioner visits and blood tests
Blood pressure lowering strategies
7. ACE inhibitor treatment: blood pressure lowering medication in conjunction with monitoring and follow up with general 
practitioner visits and blood tests.
8. Low dose diuretic treatment: blood pressure lowering medication in conjunction with monitoring and follow up with general 
practitioner visits and blood tests.
9. Low dose aspirin: Low dose aspirin in conjunction with monitoring and follow up with general practitioner visits and blood tests.
10. Calcium channel blocker: blood pressure lowering medication in conjunction with monitoring and follow up with general 
practitioner visits and blood tests.
11. Beta blocker: blood pressure lowering medication in conjunction with monitoring and follow up with general practitioner visits and 
blood tests.
12. Current practice: The combination of advice and medications currently provided in conjunction with monitoring and follow up with 
general practitioner visits and blood tests.
coMBination Blood pressure and cHolesterol lowering strategy
13. Polypill treatment: A polypill comprising a diuretic, ACE inhibitor, beta blocker and a statin, is given to each individual without 
previous history of cardiovascular disease, over the age of 55, or individuals targeted in the 3 risk groups, in conjunction with 
monitoring and follow up with general practitioner visits and blood tests. As this is currently an experimental preventive measure, 
a range of potential prices suggested by experts have been evaluated ($50, $200, $500) to assess the impact of price on cost-
effectiveness results.
4. cHoice of coMparator
The comparator to the interventions is doing nothing. This requires a hypothetical back-calculation of disease rates as if none of the 
currently used blood pressure and cholesterol lowering interventions were in place. This allows us to also evaluate the cost-effectiveness 
of current practice in comparison with all the nominated interventions.   
5. interVention cost-effectiVeness
The population based media/education campaign yields more health benefits at cost savings even when all uncertainty is taken into 
account. All other cardiovascular prevention interventions produce health benefits with a positive net cost. In the analyses of single 
interventions, the only one with a smaller chance of being cost-effective would be to provide dietary advice by a GP to every individual 
at greater than 5% risk of a cardiovascular event in the next 5 years (Table 1). It is important to take into consideration that in practice a 
combination of these interventions will be provided and that therefore the more important information is which interventions are part 
of a cost-effective package of interventions. Some of the interventions that appear to be cost-effective if analysed in isolation, are no 
longer so if added to a more cost-effective package of cardiovascular prevention options.
Table 1: Average cost-effectiveness ratios and probability of being cost-saving or cost-effective for the blood pressure and cholesterol 
lowering interventions 
* Dominant means the cost-effectiveness ratio falls in the south-east quadrant, where more benefits can be accrued at a lower cost (i.e. 
health gain with cost saving).
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Table 1: Average cost-effectiveness ratios and probability of being cost-saving or cost-
ffective for the blood pressure and holesterol lowering int rventions  
 
Intervention $Cost per DALY (95% uncertainty range) 
Probability of being under 
$50,000/DALY 
Community Heart Health Program to 
everyone regardless of risk level Health gain with cost saving 100% 
Low-dose diuretic ≥15% 600 (dominant – 6,600) 100% 
Low-dose diuretic ≥10% 1,800 (dominant – 8,600) 100% 
Low-dose diuretic ≥5% 4,200 (dominant – 13,000) 100% 
Calcium channel blocker ≥15% 6,200 (dominant – 28,000) 99% 
Calcium channel blocker ≥10% 8,200 (770 – 33,000) 99% 
Dietary counseling (dietician ≥15%) 8,600 (dominant – 35,000) 99% 
ACE inhibitor ≥15% 9,100 (3,600 – 19,000) 100% 
Dietary counseling (dietician ≥10%) 11,000 (710 – 41,000) 98% 
ACE inhibitor ≥10% 12,000 (5,400 – 23,000) 100% 
Calcium channel blocker ≥5% 12,000 (3,200 – 44,000) 98% 
Phytosterol supplementation ≥15% 14,000 (4,100 – 42,000) 99% 
Beta blocker ≥15% 14,000 (4,300 – 50,000) 98% 
Dietary counseling ( dietician ≥5%) 16,000 (3,100 – 55,000) 97% 
Beta blocker ≥10% 17,000 (6,300 – 58,000) 97% 
ACE inhibitor ≥5% 17,000 (9,100 – 32,000) 100% 
Phytosterol supplementation ≥10% 18,000 (6,000 – 50,000) 98% 
Dietary counseling (GP ≥15%) 21,000 (7,500 – 84,000) 92% 
Statin and ezetimibe ≥15% 21,000 (17,000 – 25,000) 100% 
Statin ≥15% 21,000 (15,000 – 28,000) 100% 
Beta blocker ≥5% 24,000 (10,000 – 78,000) 93% 
Phytosterol supplementation ≥5% 24,000 (9,900 – 65,000) 94% 
Dietary counseling (GP ≥10%) 25,000 (9,900 – 98,000) 88% 
Statin ≥10% 25,000 (19,000 – 34,000) 100% 
Statin and ezetimibe ≥10% 25,000 (21,000 – 29,000) 100% 
Current practice 29,000 (22,000 – 40,000) 100% 
Statin and ezetimibe ≥5% 34,000 (30,000 – 39,000) 100% 
Statin ≥5% 34,000 (26,000 – 44,000) 100% 
Dietary counseling (GP  ≥5%) 35,000 (15,000 – 130,000) 77% 
* Dominant means the cost-effectiveness ratio falls in the south-east quadrant, where more benefits can be 
accrued at a lower cost (i.e. health gain with cost saving). 
 
Whether prescribed to individuals according to their level of cardiac risk or alternatively to all persons over the age of 55, the polypill is 
very cost-effective within the price range $50 to $500 (Table 2). 
Table 2:  Cost-effectiveness ratios and probability of being cost-effective for Polypill interventions compared to doing nothing 
All interventions except the use of statins, ezetimibe, beta blockers and dietary advice by a GP, would be included in the optimal mix 
of intervention strategies to address cardiovascular disease prevention in a cost-effective manner (Figure 1). The combined package 
of these interventions could for one third of net costs prevent over 30% more disease burden than current practice. Due to high cost, 
adding the cholesterol-lowering drugs to the pathway is not cost-effective ($0.5million/DALY), far greater than the $50,000 threshold 
used in this study and would not be recommended.
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Intervention $Cost per DALY  
(95% uncertainty range) 
Probability of being 
under $50,000/DALY 
Phytosterol supplementation ≥5% 24,000 (9,900 – 65,000) 94% 
Dietary counseling (GP ≥10%) 25,000 (9,900 – 98,000) 88% 
Statin ≥10% 25,000 (19,000 – 34,000) 100% 
Statin and ezetimibe ≥10% 25,000 (21,000 – 29,000) 100% 
Current practice 29,000 (22,000 – 40,000) 100% 
Statin and ezetimibe ≥5% 34,000 (30,000 – 39,000) 100% 
Statin ≥5% 34,000 (26,000 – 44,000) 100% 
Dietary counseling (GP  ≥5%) 35,000 (15,000 – 130,000) 77% 
* Dominant means the cost-effectiveness ratio falls in the south-east quadrant, where more benefits can be 
accrued at a lower cost (i.e. health gain with cost saving). 
Whether prescribed to individuals according to their level of cardiac risk or alternatively to all 
persons over the age of 55, the polypill is very cost-effective within the price range $50 to 
$500 (Table 2).  
Table 2:  Cost-effectiveness ratios and probability of being cost-effective for Polypill interventions 
compared to doing nothing  
Intervention $Cost per DALY (95% uncertainty range) 
Probability of being under 
$50,000/DALY 
Polypill $50 to over 55 y Health gain with cost saving 100% 
Polypill $200 to over 55 y 48 (dominant – 3,400) 100% 
Polypill $500 to over 55 y 11,000 (6,700 – 16,000) 100% 
   
Polypill $50 ≥5% Health gain with cost saving 100% 
Polypill $200 ≥5% Health gain with cost saving 
(dominant – 2,000) 
100% 
Polypill $500 ≥5% 6,700 (2,800 – 11,000) 100% 
   
Polypill $50 ≥15% Health gain with cost saving 100% 
Polypill $200 ≥15% Health gain with cost saving 100% 
Polypill $500 ≥15% 2,200 (dominant – 5,800) 100% 
   
Polypill $50 ≥10% Health gain with cost saving 100% 
Polypill $200 ≥10% Health gain with cost saving (dominant – 330) 100% 
Polypill $500 ≥10% 3,700 (290 – 7,600) 100% 
   
All interventions except the use of statins, ezetimibe, beta blockers and dietary advice by a 
GP, would be included in the optimal mix of intervention strategies to address cardiovascular 
disease prevention in a cost-effective manner (Figure 1). The combined package of these 
interventions could for one third of net costs prevent over 30% more disease burden than 
current practice. Due to high cost, adding the cholesterol-lowering drugs to the pathway is 
Figure 1: An intervention pathway for the blood pressure and cholesterol lowering interventions excluding the polypill
If a polypill (a combination of three generic blood pressure lowering drugs – diuretic, calcium channel blocker and ACE-inhibitor– at half 
strength and a statin in a single pill) were introduced at an annual cost of $200 per person treated the immediate cost savings would be 
much greater still. The package would prevent more than 500,000 DALYs over the lifetime of the 2003 Australian population (Figure 2). 
We have not taken into account that adherence to a single polypill may be greater than to a larger number of pills.
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cost-effective option than use of statins only. The reason that cholesterol-lowering drugs become cost-
ineffective, if the most efficient mix of interventions is put in place first, is due to the high price of these 
drugs. 
 
 
Figure 3.1 Intervention pathway of the most cost-effective interventions for blood pressure- and cholesterol-lowering 
interventions compared to current practice. ACEi, angiotensin-converting enzyme inhibitor; CCB, calcium channel blocker; 
CHHP, community heart health program; DALY, disability-adjusted life year 
 
Phytosterol + 
Statin+Ezetimibe ≥5%
CCB + ACEi ≥5% + 
Phytosterol ≥10%
Diuretic+ Dietitian+
Phytosterol ≥5%
Diuretic+ CCB + 
Dietitian ≥10%
Diuretic+ CCB + 
Dietitian ≥15%
Diuretic
≥10%CHHP
Diuretic
≥15%
Current practice
-5,000 
-
5,000 
10,000 
15,000 
20,000 
25,000 
- 100 200 300 400 500 600 
N
et
 L
ife
tim
e 
C
os
ts
 (m
ill
io
n 
A
$ 
20
03
)
Lifetime DALYs averted ('000)
Figure 2:  An intervention pathway for the blood pressure and cholesterol lowering interventions including the polypill to risk groups at 
the price of $200 per annum 
6. conclusions
Current practice in blood pressure and cholesterol lowering is inefficient. A more efficient approach with large immediate cost savings 
is feasible if –in order of importance– (a) the most cost-effective drugs are used in preference to more expensive and less cost-effective 
drugs; (b) prevention is targeted by absolute risk rather than individual risk factor thresholds; and (c) better use is made of cost-effective 
non-drug interventions. The introduction of the polypill at a reasonable price offers to achieve the same health gain as current practice 
at a much greater net cost saving.
Acceptability to stakeholders is the most important of the second filter criteria in evaluating blood pressure and cholesterol lowering 
interventions. It will take time and effort to introduce new guidelines based on absolute risk and this may meet with resistance by 
clinicians. There may also be a degree of resistance among public health practitioners and patients against the medicalisation of 
prevention and the risk of side effects. 
For more information on this topic area, please visit website www.sph.uq.edu.au/bodce-ace-prevention
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Figure 3.2 Intervention pathway of the most cost-effective interventions for blood pressure- and cholesterol-lowering 
interventions, including the polypill, compared to current practice. ACEi, angiotensin-converting enzyme inhibitor; CCB, 
calcium channel blocker; CHHP, community heart health program; DALY, disability-adjusted life year 
 
3.4.2 Intervention pathway of alcohol interventions 
The intervention pathway for alcohol combines seven interventions to prevent alcohol-related disease 
and injury and one interventi n to treat al hol d pendence (Figure 3.3Error! Ref rence source n t 
found.). Of the seven prevention interventions, random breath testing is considered the only 
intervention with more than negligible level of implementation in current practice. The vast majority 
of the health gain is achieved by the 30% tax on alcohol. The 30% tax alone could achieve 21% of the 
population health improvements that would be achieved if all rinkers r duced their daily alcohol 
consumption to fewer than four standard drinks for men and two standard drinks for women (the 
limits that the international literature and National Health and Medical Research Council until recently 
used to describe moderate alcohol intake). A volumetric tax that is revenue-neutral would have a far 
lower impact on health than the general tax increase. Further combinations of volumetric and 
increased taxation on alcohol are provided in Appendix 2 and in a separate report [46]. 
Taxation, advertising bans and an increase in minimum legal drinking age to 21 are cost-saving 
(dominant) interventions as indicated by the downward slope in the pathway. Brief intervention by a 
GP, licensing controls, drink driving mass media and the current practice of random breath testing are 
cost-effective additions to the pathway. The slope of the line towards residential treatment (with or 
without naltrexone pharmacotherapy) is very steep. Its inclusion in the pathway is not cost-effective. 
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7. aBout ace-preVention
To aid priority setting in prevention, the Assessing Cost-Effectiveness in Prevention Project (ACE-Prevention) applies 
standardised evaluation methods to assess the cost-effectiveness of 100 to 150 preventive interventions, taking a health 
sector perspective. This information is intended to help decision-makers move resources from less efficient current 
practices to more efficient preventive action resulting in greater health gain for the same outlay.
Indigenous population results 
1.   Cardiovascular disease prevention 
2.   Diabetes prevention 
3.   Screening and early treatment of chronic kidney disease
Overall results 
1.   League table 
2.   Combined effects 
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Methods: 
A.   The ACE-Prevention project 
B.   ACE approach to priority setting 
C.   Key assumptions underlying the economic analysis 
D.   Interpretation of ACE-Prevention cost-effectiveness results 
E.   Indigenous Health Service Delivery 
General population results
1.  Adult depression
2.  Alcohol
3.  Blood pressure and cholesterol lowering
4.  Cannabis
5.  Cervical cancer screening, Sunsmart and PSA screening
6.  Childhood mental disorders
7.  Fruit and vegetables
8. HIV
9. Obesity
10. Osteoporosis
11. Physical activity
12. Pre diabetes screening
13. Psychosis
14. Renal replacement therapy, screening and early treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
